Study of new drug versus Padcev for advanced bladder and urinary tract cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial compares a new investigational drug called SYS6002 with an already approved treatment called PADCEV for advanced urothelial carcinoma (a type of bladder or urinary tract cancer). The goal is to see if SYS6002 can be as effective or better than PADCEV at slowing cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You have advanced urothelial carcinoma (cancer of the bladder or urinary tract) that has progressed after prior treatment with platinum-based chemotherapy and immunotherapy (PD-1/PD-L1 inhibitors).
- You need to have a tumor tissue sample available for testing.
- Your cancer must be measurable by imaging scans (like CT or MRI) according to standard criteria.
- Your overall health should be good, meaning you are able to do most daily activities (ECOG score 0 or 1).
- You must not have active cancer in the brain or spinal cord lining, serious heart disease, or other severe uncontrolled medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, 9MW2821, against standard chemotherapy for people with advanced bladder cancer that has gotten worse after previous treatments. It aims to see if the new drug works better.
This study tests a new drug called SYS6002 against standard chemotherapy for people with advanced bladder cancer that has grown after previous treatments. The goal is to see if SYS6002 can help slow the cancer better than chemotherapy.
This trial tests a new drug, PF-08634404, either by itself or together with another drug called enfortumab vedotin, for people with advanced bladder cancer that has spread. The goal is to see if these treatments can shrink tumors or slow the cancer's growth.
This trial adds an investigational drug, GB-4362, to a standard combination of two medicines (enfortumab vedotin and pembrolizumab) for advanced bladder cancer. The study wants to see if adding this drug is safe and helps treat the cancer better.
This trial is for people with advanced bladder cancer (urothelial cancer) that has spread or can't be removed. It tests a new drug called sacituzumab tirumotecan against standard chemotherapy options to see if it works better.
This trial tests a new drug called BL-B01D1 against standard chemotherapy for people with advanced bladder cancer that has stopped responding to platinum chemo and immunotherapy. The goal is to see if the new drug works better.
Hear when a new Advanced Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.